DexCom (NASDAQ:DXCM) Announces Quarterly Earnings Results

DexCom (NASDAQ:DXCM - Get Free Report) announced its quarterly earnings results on Thursday. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.05), Zacks reports. DexCom had a net margin of 17.22% and a return on equity of 31.40%.

DexCom Stock Performance

DexCom stock traded up $4.98 during mid-day trading on Monday, reaching $89.07. The company's stock had a trading volume of 7,591,102 shares, compared to its average volume of 3,361,682. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00. The firm has a market cap of $34.79 billion, a price-to-earnings ratio of 53.34, a PEG ratio of 2.26 and a beta of 1.14. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23. The business has a 50 day moving average price of $82.44 and a 200-day moving average price of $75.49.

Insider Activity

In related news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares in the company, valued at $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Jacob Steven Leach sold 2,634 shares of DexCom stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at approximately $23,347,850.04. This represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 42,342 shares of company stock valued at $3,628,069. 0.30% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on DXCM shares. Citigroup increased their price objective on shares of DexCom from $85.00 to $91.00 and gave the company a "buy" rating in a research note on Wednesday, December 11th. Oppenheimer decreased their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a research report on Friday, October 25th. Royal Bank of Canada cut their price target on shares of DexCom from $120.00 to $115.00 and set an "outperform" rating on the stock in a report on Friday, October 25th. Wells Fargo & Company raised their price target on shares of DexCom from $90.00 to $94.00 and gave the company an "overweight" rating in a report on Wednesday, December 11th. Finally, Sanford C. Bernstein raised their price target on shares of DexCom from $82.00 to $86.00 and gave the company an "outperform" rating in a report on Friday, October 25th. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $99.06.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.